LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
DiaSorin, Inc. · Decision date Dec 19, 2025
What did the FDA decide?
FDA records P220034/S008 as a supplement to PMA P220034, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 19, 2025.
FDA approval order statement
a new supplier has been added for DiaSorins accessory
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Dec 19, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P220034/S008
- Regulatory pathway
- PMA supplement
- Applicant
- DiaSorin, Inc.
- Product code
- MYL
- Decision code
- OK30
- Decision date
- Dec 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG.
- Applicant
- DiaSorin, Inc.
- Product code
- MYL
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220034/S007 · Related supplement
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
P220034/S008 received
Application receipt date recorded by FDA.
P220034/S008 · FDA decision
30-Day Notice
P220034/S011 · Related supplement
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
P220034/S010 · Related supplement
LIAISON Biotrin Parvovirus B19 IgG Plus; LIAISON Biotrin Control Parvovirus B19 IgG Plus
Timeline entries are records held by MedtechLedger for P220034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | PMA supplement | Oct 10, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Jun 24, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | Aug 18, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
DiaSorin, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1951 Northwestern Ave., Stillwater, MN, 55082
Sources and methodology
- Original FDA record: P220034/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
